FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1992628941> ?p ?o ?g. }

• W1992628941 endingPage "292" @default.
• W1992628941 startingPage "289" @default.
• W1992628941 abstract "The introduction of a-interferon (IFN-a) in the early 1980s contributed to an increase of overall survival compared to chemotherapy of about 20 months. Furthermore, the complete response in some patients treated in chronic phase was ascribed to its immunomodulatory effect, i.e., upregulation of HLA class I and II and of adhesion molecules. Allogeneic haematopoietic stem cell transplantation (HSCT), in addition to the diminution and eradication of some of the tumour burden by high dose pretransplant chemo and radiotherapy regimens, provides an allogeneic antitumour effect or graftversus-leukaemia (GVL) effect and truly constitutes the only current curative treatment for chronic myeloid leukemia (CML). Thus, the major curative effect of allogeneic HSCT is due to immune responses directed against malignant cells, either targeting specific tumour markers (antigens) or, more likely, individual-to-individual antigenic differences between the donor and recipient. Donor lymphocyte infusion (DLI) has been shown to cure 20/80% of the patients with relapsed leukaemia or lymphoma depending on the type and extent of the disease. However, graft-verses-host disease (GVHD) often accompanies treatment using unmodified DLI. In vitro selection and expansion of cytotoxic T lymphocytes (CTL) with relative specificity for the malignant cells may separate the anti leukemic responses from GVHD. Although ‘‘proof of principle’’ for this approach has been demonstrated in a number of patients by successful eradiation of the relapsed haematological malignancy by infusion of leukaemia reactive CTL, therapeutic numbers of Tcells with the desired antigen specificities are difficult to obtain and process in vitro. Moreover, with a very small number of exceptions, such as the minor Histocompatibility antigens HA-1 and HA-2, the differences between individuals that are capable of giving rise to these beneficial immune antitumour responses and not to a detrimental anti-host reaction, GVHD, have not been characterized. In consequence, this potentially immunotherapeutic effect of allogeneic transplantation has so far been an untargeted and unpredictable property of stem cell transplantation (SCT). Suitable targets for tumour immunotherapy fall into a number of discrete classes." @default.
• W1992628941 created "2016-06-24" @default.
• W1992628941 creator A5020482451 @default.
• W1992628941 creator A5063566874 @default.
• W1992628941 creator A5070974819 @default.
• W1992628941 date "2005-09-01" @default.
• W1992628941 modified "2023-09-23" @default.
• W1992628941 title "Immunotherapeutic aspects of stem cell transplantation" @default.
• W1992628941 cites W2003583275 @default.
• W1992628941 cites W2016241358 @default.
• W1992628941 cites W2062074417 @default.
• W1992628941 cites W2132234973 @default.
• W1992628941 cites W2142274118 @default.
• W1992628941 cites W2144004068 @default.
• W1992628941 cites W2319466579 @default.
• W1992628941 doi "https://doi.org/10.1080/10245330512331390131" @default.
• W1992628941 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16188689" @default.
• W1992628941 hasPublicationYear "2005" @default.
• W1992628941 type Work @default.
• W1992628941 sameAs 1992628941 @default.
• W1992628941 citedByCount "4" @default.
• W1992628941 countsByYear W19926289412012 @default.
• W1992628941 countsByYear W19926289412018 @default.
• W1992628941 crossrefType "journal-article" @default.
• W1992628941 hasAuthorship W1992628941A5020482451 @default.
• W1992628941 hasAuthorship W1992628941A5063566874 @default.
• W1992628941 hasAuthorship W1992628941A5070974819 @default.
• W1992628941 hasConcept C126322002 @default.
• W1992628941 hasConcept C203014093 @default.
• W1992628941 hasConcept C28328180 @default.
• W1992628941 hasConcept C2911091166 @default.
• W1992628941 hasConcept C502942594 @default.
• W1992628941 hasConcept C54355233 @default.
• W1992628941 hasConcept C71924100 @default.
• W1992628941 hasConcept C86803240 @default.
• W1992628941 hasConceptScore W1992628941C126322002 @default.
• W1992628941 hasConceptScore W1992628941C203014093 @default.
• W1992628941 hasConceptScore W1992628941C28328180 @default.
• W1992628941 hasConceptScore W1992628941C2911091166 @default.
• W1992628941 hasConceptScore W1992628941C502942594 @default.
• W1992628941 hasConceptScore W1992628941C54355233 @default.
• W1992628941 hasConceptScore W1992628941C71924100 @default.
• W1992628941 hasConceptScore W1992628941C86803240 @default.
• W1992628941 hasIssue "sup1" @default.
• W1992628941 hasLocation W19926289411 @default.
• W1992628941 hasLocation W19926289412 @default.
• W1992628941 hasOpenAccess W1992628941 @default.
• W1992628941 hasPrimaryLocation W19926289411 @default.
• W1992628941 hasRelatedWork W1972104255 @default.
• W1992628941 hasRelatedWork W2040079807 @default.
• W1992628941 hasRelatedWork W2119511363 @default.
• W1992628941 hasRelatedWork W2355849122 @default.
• W1992628941 hasRelatedWork W2463480543 @default.
• W1992628941 hasRelatedWork W2972524456 @default.
• W1992628941 hasRelatedWork W3031522679 @default.
• W1992628941 hasRelatedWork W3120507315 @default.
• W1992628941 hasRelatedWork W4239196561 @default.
• W1992628941 hasRelatedWork W4310781886 @default.
• W1992628941 hasVolume "10" @default.
• W1992628941 isParatext "false" @default.
• W1992628941 isRetracted "false" @default.
• W1992628941 magId "1992628941" @default.
• W1992628941 workType "article" @default.